medigraphic.com

2021, Number 4

<< Back Next >>

Enf Infec Microbiol 2021; 41 (4)

Vaccination in Down syndrome children

Baeza CJA, Juárez CCE, Reyes GU, Espinosa SMC, Guerrero BM, Reyes HKL, González OAM, Almonte DAE, Alonso PNC

Language: Spanish
References: 44
Page: 162-167
PDF size: 181.37 Kb.


ABSTRACT

Down syndrome children have high morbidity and mortality due to infectious diseases, especially of the respiratory tract, especially in the first five years of life, all due to immune dysfunctions of T lymphocytes associated with the syndrome and other factors such as: their functional neurological and behavioral disability and the coexistence in some cases of anomalies of the cardiac and respiratory systems mainly due to congenital pathologies, among others. This review is a proposal for specific immunizations for this risk group, and a review of each of the biologics indicated therein. It highlight avoid the missed opportunities and emphasizing the application of the booster dose given that the immunocellular response in them is incomplete.


REFERENCES

  1. Mateos, A.M., “Inmunidad en el síndrome de Down”, en Corretger, J.M., Serés, A., Casaldàliga, J. y Trias, K. (eds.), Síndrome de Down. Aspectos médicos actuales, Barcelona, Masson, 2005, pp. 109-117.

  2. Nespoli, L., Burgio, G.R., Ugazio, A.G. y Maccario, R., “Immunological features of Down’s syndrome: a review”, J Intel Disabil Res, 1993, 37: 543-551.

  3. De Hingh, Y.C.M., Van der Vossen P.W., Gemen, E.A. et al., “Intrinsic abnormalities of lymphocyte counts in children with Down syndrome”, J Pediatr, 2005, 147: 744-747.

  4. Wats, R. y Vyas H., “An overview of the respiratory problems in children with Down’s syndrome”, Arch Dis Child, 2013, 98: 812-817.

  5. Bloemers, B.L., Van Furth, A.M., Weijerman, M.E. et al., “Down syndrome: a novel risk factor for respiratory syncitial virus bronchiolitis: a prospective birth-cohort study”, Pediatrics, 2017, 120: 1076-1081.

  6. Corretger, R.J., “Vacunaciones y calendario de vacunaciones en el síndrome de Down”, Vacunas, 2012, 13: 112-117.

  7. Breuer, B., Friedman, S.M., Millner, E.S. et al., Transmision of hepatitis b virus to classroom contacts of mentally retarded carriers”, jama, 1985, 254: 3190-3195.

  8. García, B.M., Legarda, J.J., Cortés, A. et al., “Los deficientes mentales y la infección por el virus de la hepatitis b. Prevalencia en nuestro medio”, Med Clin (Barcelona), 1989, 93: 10-13.

  9. Nisihara, R., De Bem, R.S., Negreiros, P.H., Utiyama, S.R., Oliveira, N.P. y Amarante, H., “Low hepatitis b vaccine response in children with Down syndrome from Brazil”, Child Care Health Dev, 2014, 40: 607-609.

  10. Aristegui-Fernández, J., Cisterna-Cáncer, R., Muñiz-Saltua, J. et al., “Prevalencia de infección por el virus de la hepatitis b en instituciones de deficientes mentales. Características epidemiológicas en la provincia de Vizcaya”, Med Clin (Barcelona), 1989, 92: 323-327.

  11. Rua, A.M.J., Ramírez, M.V., Onaindia, E.M.T. et al., “Predisposición del síndrome de Down a la infección crónica por el virus b de la hepatitis”, An Esp Pediatr, 1993, 38: 529-531.

  12. Di Ciommo, V., Ferrario, F., Rossi de Gasperi, M., et al., “Epidemiology of hepatitis b virus in non institutionalized children and adolescents affected by handicap”, J Intel Disabil Res, 1993, 37: 295-299.

  13. Wahl, M., Hermodason, S. e Iwarson, S., “Immune response to hepatitis b vaccine in the mentally retarded”, J Infect, 1983, 7 (Suppl 1): s47-s51.

  14. García, O., Bruguera, M., Mayor, J.M. et al., “Hepatitis b en una institución abierta para retrasados mentales. Efecto inmunogénico de una vacuna recombinante antihepatitis b”, Enf Inf Microbiol Clin, 1990, 8: 148-152.

  15. Krugman, S.. “Hepatitis b carriers in the classroom” (Editorial), jama, 1985, 254: 3218-3219.

  16. Avanzini, M.A., Monafo, V., De Amici, M. et al., “Humoral immunodeficiencies in Down syndrome: serum igg subclass and antibody response to hepatitis b vaccine” (Carta al Editor), Am J Med Genet, 1990, Suppl 7: 231- 233.

  17. Piccione, M., De Curtis, M., La Vecchia, M.L. et al., “Hepatitis b and c infection in children with Down syndrome”, Eur J Pediatr 1997, 156: 420-421.

  18. Ward, R., Borchert, P., Wright, A. y Kline, E., “Hepatitis b antigen in saliva and mouth washings”, The Lancet, 1972, 2: 726-727.

  19. Troisi, C.L., Heiberg, D.A. y Blaine Hollinger, F., “Normal immune response to hepatitis b vaccine in patients with Down syndrome. A basis for immunization guidelines”, jama, 1985, 254: 3196-3199.

  20. Cobo-Soriano, J., Gil-Miguel, A., Rey-Calero, J. et al., “Inmunogenicidad de la vacuna contra el Vhb en deficientes mentales”, At Primaria, 1991, 8: 536-541.

  21. Vajro, P., Letrera, P., Fontanella, A. et al., “Vaccination against hepatitis b in preschool children with Down’s syndrome”, J Intel Disabil Res, 1992, 36: 77-81.

  22. Avanzini, M.A., Söderström, T., Wahl, M. et al., “igg subclass deficiency in patients with Down’s syndrome and aberrant hepatitis b vaccine response”, Scand J Immunol, 1988, 28: 465-470. sd 2008, Revista Mèdica Internacional sobre el Síndrome de Down 23, 12 (2): 18-24.

  23. Corretger, J.M. y Baraibar, R., “Vacunaciones en niños con enfermedades crónicas”, en Aristegui, J. (ed.), Vacunaciones en el niño. De la teoría a la práctica, Bilbao, Ciclo, 2004, pp. 880-882.

  25. Mateos, A.M., “Inmunidad en el síndrome de Down”, en Corretger, J.M., Serés, A., Casaldàliga, J. y Trias, K. (eds.), Síndrome de Down. Aspectos médicos actuales, Barcelona, Masson, 2005, pp. 109-117. 2. Nespoli, L., Burgio, G.R., Ugazio, A.G. y Maccario, R., “Immunological features of Down’s syndrome: a review”, J Intel Disabil Res, 1993, 37: 543-551. 3. De Hingh, Y.C.M., Van der Vossen P.W., Gemen, E.A. et al., “Intrinsic abnormalities of lymphocyte counts in children with Down syndrome”, J Pediatr, 2005, 147: 744-747. 4. Wats, R. y Vyas H., “An overview of the respiratory problems in children with Down’s syndrome”, Arch Dis Child, 2013, 98: 812-817. 5. Bloemers, B.L., Van Furth, A.M., Weijerman, M.E. et al., “Down syndrome: a novel risk factor for respiratory syncitial virus bronchiolitis: a prospective birth-cohort study”, Pediatrics, 2017, 120: 1076-1081. 6. Corretger, R.J., “Vacunaciones y calendario de vacunaciones en el síndrome de Down”, Vacunas, 2012, 13: 112-117. 7. Breuer, B., Friedman, S.M., Millner, E.S. et al., Transmision of hepatitis b virus to classroom contacts of mentally retarded carriers”, jama, 1985, 254: 3190-3195. 8. García, B.M., Legarda, J.J., Cortés, A. et al., “Los deficientes mentales y la infección por el virus de la hepatitis b. Prevalencia en nuestro medio”, Med Clin (Barcelona), 1989, 93: 10-13. 9. Nisihara, R., De Bem, R.S., Negreiros, P.H., Utiyama, S.R., Oliveira, N.P. y Amarante, H., “Low hepatitis b vaccine response in children with Down syndrome from Brazil”, Child Care Health Dev, 2014, 40: 607-609. 10. Aristegui-Fernández, J., Cisterna-Cáncer, R., Muñiz-Saltua, J. et al., “Prevalencia de infección por el virus de la hepatitis b en instituciones de deficientes mentales. Características epidemiológicas en la provincia de Vizcaya”, Med Clin (Barcelona), 1989, 92: 323-327. 11. Rua, A.M.J., Ramírez, M.V., Onaindia, E.M.T. et al., “Predisposición del síndrome de Down a la infección crónica por el virus b de la hepatitis”, An Esp Pediatr, 1993, 38: 529-531. 12. Di Ciommo, V., Ferrario, F., Rossi de Gasperi, M., et al., “Epidemiology of hepatitis b virus in non institutionalized children and adolescents affected by handicap”, J Intel Disabil Res, 1993, 37: 295-299. 13. Wahl, M., Hermodason, S. e Iwarson, S., “Immune response to hepatitis b vaccine in the mentally retarded”, J Infect, 1983, 7 (Suppl 1): s47-s51. 14. García, O., Bruguera, M., Mayor, J.M. et al., “Hepatitis b en una institución abierta para retrasados mentales. Efecto inmunogénico de una vacuna recombinante antihepatitis b”, Enf Inf Microbiol Clin, 1990, 8: 148-152. 15. Krugman, S.. “Hepatitis b carriers in the classroom” (Editorial), jama, 1985, 254: 3218-3219. 16. Avanzini, M.A., Monafo, V., De Amici, M. et al., “Humoral immunodeficiencies in Down syndrome: serum igg subclass and antibody response to hepatitis b vaccine” (Carta al Editor), Am J Med Genet, 1990, Suppl 7: 231- 233. 17. Piccione, M., De Curtis, M., La Vecchia, M.L. et al., “Hepatitis b and c infection in children with Down syndrome”, Eur J Pediatr 1997, 156: 420-421. 18. Ward, R., Borchert, P., Wright, A. y Kline, E., “Hepatitis b antigen in saliva and mouth washings”, The Lancet, 1972, 2: 726-727. 19. Troisi, C.L., Heiberg, D.A. y Blaine Hollinger, F., “Normal immune response to hepatitis b vaccine in patients with Down syndrome. A basis for immunization guidelines”, jama, 1985, 254: 3196-3199. 20. Cobo-Soriano, J., Gil-Miguel, A., Rey-Calero, J. et al., “Inmunogenicidad de la vacuna contra el Vhb en deficientes mentales”, At Primaria, 1991, 8: 536-541. 21. Vajro, P., Letrera, P., Fontanella, A. et al., “Vaccination against hepatitis b in preschool children with Down’s syndrome”, J Intel Disabil Res, 1992, 36: 77-81. 22. Avanzini, M.A., Söderström, T., Wahl, M. et al., “igg subclass deficiency in patients with Down’s syndrome and aberrant hepatitis b vaccine response”, Scand J Immunol, 1988, 28: 465-470. sd 2008, Revista Mèdica Internacional sobre el Síndrome de Down 23, 12 (2): 18-24. 23. Corretger, J.M. y Baraibar, R., “Vacunaciones en niños con enfermedades crónicas”, en Aristegui, J. (ed.), Vacunaciones en el niño. De la teoría a la práctica, Bilbao, Ciclo, 2004, pp. 880-882. 24. Hawkes, R.A., Boughton, C.R. y Shroeter, D.R., “The antibody response of institutionalized Down’s syndrome to seven microbial antigens”, Clin Exp Immunol, 1978, 31: 298-304. 25.LiVolti, S., Mattina, T., Mauro, L. et al., “Safety and effectiveness of an acellular pertussis vaccine in subjects with Down’s syndrome”, Childs Nerv Syst, 1996, 12: 100-102.

  26. Hawkes, R.A., Philbrook, S.C. y Boughton, C.R., “The response of institutionalized Down’s syndrome subjects to enterovirus infections”, J Hyg Camb, 1980, 84: 433-441.

  27. Hawkes, R.A. y Philbrook, S.C., “The response of institutionalized Down’s syndrome subjects to enterovirus infections”, J Hyg, 1980, 84: 433-441.

  28. LiVolti, S., Mattina, T., Mauro, L. et al., “Safety and effectiveness of an acellular pertussis vaccine in subjects with Down’s syndrome”, Childs Nerv Syst, 1996, 12: 100-102.

  29. Griffiths, A.W. y Sylvester, P.E., “Mongols and nonmongols compared in their response to active tetanus immunization”, J Ment Def Res, 1867, 11: 263-266.

  30. Nurmi, T., Leinonen, M., Haiva, V.M. et al., “Antibody response to pneumoccoccal vaccine in patients with trisomy-21 (Down’s syndrome)”, Clin Expo Immunol, 1982, 48: 485-490.

  31. Costa-Carvalho, B.T., Martinez, R.M.A., Dias, A.T.N. et al., “Antibody response to pneumococcal capsular vaccine in Down syndrome patients”, Braz J Med Res, 2006, 39: 1587-1592.

  32. Jiménez, P. y Serviá, M., “Análisis descriptivo de las meningitis por Streptococcus pneumoniae en un hospital terciario”, Neurol Arg, 2012, 4 (1): 6-10.

  33. Black, S., Nicolay, U., Vesikari, T., Knuf, M., Del Giudice, G., Della Cioppa, G. et al., “Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children”, Pediatr Infect Dis J, 2011, 30: 1081-1085.

  34. Gordon, M.G. y Sinha, S.K., “Antibody responses to influenza vaccine in patients with Down’s syndrome”, Am J Ment Def, 1971, 75: 391-399.

  35. Pérez, P.R., Fernández, R., García, S.C., Franco, M.F., Aburto, O., López, G.H. et al., “Pandemic (h1n1) 2009 virus and Down syndrome patients”, Emerg Infect Dis, 2010, 16: 1312-1314.

  36. Ferreira, C.T., Leite, J.C., Taniguchi, A. et al., “Immunogenicity and safety of an inacivated hepatitis a vaccine in children with Down syndrome”, Pediatr Gastroenterol Nutr, 2004, 39: 337-340.

  37. CDC, “Prevention of hepatitis a through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (acip)”, mmwr Recomm Rep, 2006, 55 (rr-7): 1-23.

  38. Joshi, A.Y., Abraham, R.S., Synder, R.S. y Boyce, T.G., “Immune evaluation and vaccine responses in Down syndrome: evidence of immunodeficiency?”, Vaccine, 2011, 29: 5040-5046.

  39. Costa, C.B.T., Martínez, M.A., Dias, A.T.N., Kubo, C.A., Barrios-Nunes, P., Leiva, L. et al., “Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients”, Braz J Med Biol Res, 2006, 39: 1587-1592.

  40. Corretger, R.J.M. el al., “Vacunaciones en el niño con síndrome de Down”, Rev Pediatr Aten Primaria, 2014, 16: 159-167.

  41. CDC, “hpv vaccine information for young women”. Disponible en: https://www.cdc.gov/std/hpv/stdfact-hpv-vaccine- young-women.html.

  42. CDC, “Recommends meningococcal vaccines for preteens, teens, and certain other people”. Disponible en: https://www.cdc.gov/meningococcal/vaccine-info-sp. html.

  43. Paes, B., Mitchell, I., Yi, H., Yi, B. y Lanctot, L.K., “Hospitalization for respiratory syncitial virus illnes in Down syndrome following prophylaxis with paivizumab”, Pediatr Infect Dis, 2014, 33: e29-33.

  44. Figueras, A. et al., “Virus respiratorio sincitial y síndrome Down”, Rev Med In Sindrome Down, 2011, 15: 33.




2020     |     www.medigraphic.com